|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatoid adenocarcinoma of the colon in a patient with inflammatory bowel disease显示文摘A case is presented of a 36-year-old male with primary sclerosing cholangitis-associated inflammatory bowel disease(PSC-IBD) and two synchronous stage 1 adenocarcinomata of the colon,who was initially treated with a subtotal colectomy with ileostomy.One year later,the patient presented with extensive intra-abdominal lymphadenopathy and peritoneal carcinomatosis,as well as a markedly elevated serum level of alpha-fetoprotein(AFP).Fine needle aspiration biopsy of a porta hepatis lymph node revealed a metastatic hepatoid adenocarcinoma.Subsequent review of the previous colectomy specimen showed that one of the previously identified adenocarcinomata had features suggestive of a hepatoid colonic adenocarcinoma.The patient was subsequently treated with a cytotoxic regimen of FOLFOX(oxaliplatin,leucovorin,5-fluorouracil) and bevacizumab,with stable results being achieved after six months.This case presents the first known report of PSC-IBD associated with synchronous typical and hepatoid adenocarcinomata of the colon and highlights the importance of considering hepatoid adenocarcinoma as a differential diagnosis in patients with an increasing serum AFP level. | Yuanyuan Chen David F Schaeffer Eric M Yoshida | 2014 | World Journal of Gastroenterology2014，20，35： | 6 |
| 2 | Expres- sion of insulin-like growth factor 2 in mesenchymal neoplasms显示文摘 | Steigen Sonja E Schaeffer David F West Robert B | 2009 | Mod Pathol2009，22，7： | 1 |
| 3 | Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adeno- carcinoma correlates with poor survival 显示文摘 | Schaeffer David F Owen Daniel R Lim Howard J | 2010 | BMC Cancer2010，59，10： | 1 |
| 4 | Unusual case of drug-induced cholestasis due to glucosamine and chondroitin sulfate显示文摘Glucosamine(GS) and chondroitin sulfate(CS) are common over-the-counter(OTC) supplements used in the treatment of osteoarthritis. These medications are seemingly safe, but there are increasing reports of hepatotoxicity with these supplements. We reported a unique case of drug-induced cholestasis caused by GS and CS in a combination tablet. The etiology of the jaundice was overlooked despite extensive investigations over a three-month period. Unlike drug-induced hepatocellular injury, drug-induced cholestatic jaundice with GS and CS has only been reported twice before. This case emphasizes the importance of a complete medication history, especially OTC supplements, in the assessment of cholestasis. | Stephen Ip Rachel Jeong David F Schaeffer Eric M Yoshida | 2015 | World Journal of Hepatology2015，7，24： | 1 |
| 5 | Comparison of Biopsy Samples Obtained Using Standard Endoscopic Instruments and the Harmonic Scalpel During Laparoscopic and Laparoscopic-Assisted Surgery in Normal Dogs 显示文摘 | Roy F Barnes Cathy L Greenfield David J Schaeffer | 2006 | Veterinary Surgery2006，35，3： | 1 |
| 6 | Severe cholestasis due to adalimumab in a Crohn's disease patient显示文摘Elevation of liver biochemistry has been reported with anti-tumor necrosis factor agents, but overt liver failure rarely reported. Autoimmune hepatitis has been more commonly reported with infliximab than adalimumab(ADA). Our case, however, describes the first reported case of ADA-associated severe cholestatic injury. A 39-year-old female with Crohn's disease developed severe jaundice after initiation of ADA. All serologic tests and imaging studies were normal. Liver biopsy showed prominent pericentral canalicular cholestasis,without features of steatosis or sclerosing cholangitis,consistent with drug-induced cholestasis. The serum total bilirubin peaked at 280 μmol/L, and improvement was seen after 5 wk with eventual normalization of liver enzymes at 10 wk. Our case describes the first reported case of ADA-associated severe cholestatic liver disease and the first histopathologic examination of this adverse drug effect. Clinicians need to be aware of this potential drug-induced liver injury when prescribing this commonly used biologic medication. | Edward Kim Brian Bressler David F Schaeffer Eric M Yoshida | 2013 | World Journal of Hepatology2013，5，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员